A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line
treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a
maintenance treatment of Pemetrexed and Bevacizumab. Treatment will continue until disease
progression or unacceptable toxicity occurs. The primary objective of this study is to
measure how long this treatment could prevent the disease progression.